
How space weather impacts us: A look at some of the worst solar storms in history
Despite its impressive magnitude — the flare was an X-class, the most severe type of solar flare — it went largely unnoticed to those on the ground not dialled in to space news.
But geomagnetic storms and more serious types of space weather, which can follow solar flares, have the ability to shut down power grids, disrupt aircraft routes, global communications and GPS, and damage satellites and spacecraft.
It has not only happened to us before, but it could happen again.
On Sept. 1, 1859, amateur astronomers Richard Carrington and Richard Hodgson both witnessed a massive flare of light from the sun's surface while observing a cluster of sunspots.
Within a day, a geomagnetic storm had struck the Earth, sparking dazzling arrays of aurora borealis and knocking out telegraph systems across Europe and North America.
Telegraph operators across Europe and North America found their systems overwhelmed and signals down, with some wires overheating so much they triggered fires. Other workers unplugged batteries only to find that the telegraph systems kept humming away, supercharged by the sun.
One superintendent from Boston, Mass., whose observations were recorded in an 1860 article in the American Journal of Science, reported that a telegraph wire between Boston and Fall River "had no battery connected with it on Saturday, and yet there was a current upon it during the entire day."
So what happened?
How space weather works
Today, experts believe that the 1859 geomagnetic storm, now known as the Carrington Event, was caused by at least one, or possibly two, coronal mass ejections (CME).
These are immense eruptions of solar material that often follow a solar flare.
Because the sun's equator rotates faster than its poles, its magnetic fields can get tangled up. When the strain gets too severe, these magnetic fields can snap, releasing a burst of energy or solar material out into space. A solar flare emits radiation that interacts with our upper atmosphere, impacting radio signals, without really affecting us on the ground.
But a CME is a massive eruption of charged particles and plasma, sometimes millions of miles wide, which can travel up to thousands of kilometres per second on solar winds. When its magnetic field slams into the Earth's, it can spark geomagnetic storms that disrupt critical infrastructure. In 1859, that was telegraph operations, but today, it's power grids, satellites and global navigation systems.
Because the northern lights are caused by charged particles interacting with our magnetic field at the poles, a CME can also cause dramatic displays of aurora borealis, like the ones seen during geomagnetic storms in October and May 2024.
Although they can occur independently of each other, stronger solar flares are often accompanied by CMEs, according to Robyn Fiori, a research scientist in the space weather group of the Canadian Hazards Information Service with Natural Resources Canada.
"There's lots of different critical systems that can be impacted by space weather. So it's a good idea to keep track of what's going on," she said.
Canada's solar storm of 1989
The last big solar event to have a notable impact on a power grid was in 2003, Fiori said, when a number of geomagnetic storms known as "the Halloween storms" rerouted aircraft, affected GPS systems used for deep-sea drilling, prompted astronauts in the International Space Station to take shelter from radiation in a specific part of the station, damaged a Japanese satellite beyond repair and triggered a power outage in Malmö, Sweden.
This event included a flare so large it overwhelmed the X-ray detectors on a number of satellites. It was later estimated to be an X28 flare, according to the European Space Agency, making it the most powerful in recorded observational history.
The biggest solar storm in Canada's history came in March 1989, when a CME struck Earth's magnetic field, sending electric currents flowing through the rock of the Canadian Shield to the transmission lines of Hydro-Quebec. The resulting province-wide blackout left millions of residents in the darkness and cold for nine hours.
"That's the strongest event that we've had in this technological age," Fiori said, "and it's really what we've used as a benchmark to make sure that systems are safe."
Other notable solar storms include one in 1909 that disrupted telegraph lines across the U.S., and one in 1967 that jammed radar systems operating in Alaska, Greenland and the U.K. amid mounting tensions between NATO and the Soviet Union, briefly sparking concerns of a Soviet attack.
It's been more than two decades since a solar storm caused significant power fluctuations and communications disruptions, but in an increasingly technological world, it's something space forecasters are keeping an eye on to stay a step ahead of the next solar storm.
For the next year or so, solar flares and solar activity will be higher than usual, as we're within the period of solar maximum, the peak of the sun's 11-year cycle.
"We do have a lot of different technologies that are sensitive to space weather. Since 1989, for example, we've become much more dependent on GNSS or GPS for navigation. And that can be impacted by space weather," Fiori said.
She added that Canada, due to its proximity to the northern magnetic pole, is more vulnerable to space weather.
"But it also means that we're in the very best place to observe it so that we can build accurate forecasts."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


National Post
4 hours ago
- National Post
IQM to Integrate Quantum Computer Into Oak Ridge National Laboratory's HPC Systems
IQM Radiance 20-qubit upgradeable full stack superconducting quantum computer will be the first on-premises quantum computer at Oak Ridge National Laboratory (ORNL). The system will be delivered by the third quarter of 2025, and it will be integrated with ORNL's high-performance computing (HPC) systems to advance hybrid quantum-classical application development. Article content Article content TENNESSEE, USA & ESPOO, Finland — The Department of Energy's Oak Ridge National Laboratory (ORNL) today announced it has selected IQM Radiance as its first-ever purchased on-premises quantum computer to be integrated into high-performance computing (HPC) systems at ORNL. Article content Article content IQM Radiance 20-qubit quantum computer is based on superconducting technology and aimed at accelerating hybrid quantum-classical application development. The quantum computer will be delivered by the third quarter of 2025 and is upgradeable to higher qubit counts in the future. Article content Acquiring an on-premises IQM Radiance supports ORNL's mission to work towards seamless, tight integration between quantum computing hardware and HPC infrastructure. ORNL's teams have been recognised for leading quantum-HPC integration efforts in the research community for years. Article content Today's announcement follows an earlier announcement of ORNL's Quantum Computing User Program (QCUP) leveraging the IQM Resonance cloud platform for advanced quantum research. Article content 'ORNL has a decades-long history in high-performance computing and is today one of the leading research institutions in the US for quantum computing,' said Travis Humble, advisor to the QCUP and director of the Quantum Science Center at ORNL. 'IQM's on-premises installation will allow our researchers hands-on access to cutting-edge quantum computing technology as we explore how quantum computers will be integrated with HPC systems to tackle early quantum advantage.' Article content 'We are excited that ORNL has selected IQM Radiance as their first-ever purchased on-premises quantum computer,' said Mikko Välimäki, Co-CEO of IQM Quantum Computers. 'This further proves that quantum computers are already today highly useful and in demand. Important research can be done to integrate quantum computers with classical hardware and develop the platform for quantum advantage.' Article content Since entering the US market, IQM has been leveraging its leading global market position, state-of-the-art technology, and partnerships to drive quantum research, adoption and education. Article content 'We are committed to supporting ORNL's pioneering efforts to advance quantum computing across the US. Our shared vision to accelerate the integration of quantum and HPC infrastructure has made this journey incredibly rewarding, and we are just getting started. Our long-term goal is to collaborate closely with ORNL's researchers in quantum application areas like fluid dynamics, particle physics and electronic structure simulations,' said Jan Goetz, co-founder and co-CEO of IQM. Article content About IQM Quantum Computers: Article content IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea and the United States. Article content Article content Article content Article content Article content Contacts Article content Media contact: Article content Article content Email: Article content Article content

National Post
7 hours ago
- National Post
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
Article content LEXINGTON, Mass. — Agenus Inc. ('Agenus') (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A. Article content Speakers to Include: Article content Article content Garo H. Armen, PhD Article content Founder, Chairman, CEO of Agenus Article content Jennifer Buell, PhD CEO of MiNK Therapeutics/ Chair of Executive Committee of Agenus Article content Richard M. Goldberg, MD Chief Development Officer of Agenus (joined May 2025) GI oncology expert with 40+ years in CRC research Article content Nicholas C. DeVito, MD Assistant Professor of Medical Oncology at Duke University Primarily treats patients with CRC and gastroesophageal cancers Research focused on tumor immune evasion and immunotherapy Article content Chris O'Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG): Senior Investigators at Canadian Cancer Trials Group (CCTG) Stakeholder Briefing Details: Webcast Link | Audience Conference Call Registration Link | Conference ID: 73242 Article content About Agenus Article content Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. Article content About Botensilimab (BOT) Article content Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Article content Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. Approximately 1,200 patients have been treated across the botensilimab/balstilimab program in phase 1 and phase 2 clinical trials. For more information about botensilimab trials, visit Article content About Balstilimab (BAL) Article content Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Article content Forward-Looking Statements Article content This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations and regulatory plans, and the potential benefits of the combination therapy. Words such as 'may,' 'believes,' 'expects,' 'anticipates,' 'hopes,' 'intends,' 'plans,' 'forecasts,' 'estimates,' 'will,' 'potential,' 'game-changing,' 'curative,' and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the 'Risk Factors' section of Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on forward-looking statements in this release, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Article content Article content Article content Article content Contacts Article content Investors Article content Article content 917-362-1370 |


CBC
8 hours ago
- CBC
'Not taking any chances,' Ontario researcher closes lab after premier warns to stop testing on dogs
Social Sharing Less than a week after Ontario Premier Doug Ford vowed to "start hunting down" scientists who use cats and dogs in medical testing studies, one Ottawa-based researcher says he is shutting down his lab. "It was enormously scary," said Carleton University Canada research professor Andy Adler, who closed his project lab at the university on Friday. "I talked to a number of people in the research ethics office here and I was told that the kind of stuff I'm doing is extremely non-invasive and that I shouldn't need to worry, but here's the premier of Ontario threatening to hunt me down," Adler said. "I was scared." Last Tuesday, Premier Doug Ford told a press conference in Windsor that it was unacceptable for canines to be used in cardiac research that was approved by London's Lawson Research Institute and St. Joseph's Health Care London. "I have now directed our team to start hunting down anyone else doing research on dogs or cats," Ford said. "If you're doing this with dogs or cats, you gotta stop before I catch you. ... We're going to legislate this ... You aren't gonna be going after animals like that." A day earlier, St. Joseph's said it would immediately end all research involving dogs"following consultations with the province." Neither the hospital nor the premier's office responded to CBC News' questions about whether the province directly ordered the cardiac testing to end. Adler's research lab was working on developing improved veterinary monitoring technology, meant to help veterinarians check large animals' lungs and blood flow during daily surgeries, ensuring that animals remain stable throughout the process. His lab was creating a new type of stick-on electrode to be used in these scenarios that can reach around animals' fur, so veterinarians will not need to shave them. "The dog market is big. There are lots of dogs and lots of dogs get surgery," Adler said. "There is a big need to have improved instruments to help to do that kind of care better." Animal testing at Adler's lab involved putting typical monitoring jackets and the newly-built electrodes on service animals working at the university, allowing researchers to compare the efficacy. He has done the exact same type of testing on horses, and similar work on dolphins and sea lions, he said. "This is very non-invasive stuff that we're doing here at Carleton," Adler said, adding that he has previously done more invasive testing outside of the school that involved euthanizing dogs. Still, he said Ford's statement comes across as all-inclusive. "The Premier wasn't just saying, 'If you are doing something egregious, [you will be hunted down]', but 'If you are doing any research at all on cats and dogs, you will be hunted down,'" Adler said. "This is super threatening language and is explicitly intended to cover people like me who are doing very non-invasive work." "I'm not taking any chances." The premier's office did not respond to CBC's questions about whether he plans to end all types of research or dogs and cats, or if there could be exceptions. St. Joseph's creating research 'transition plan' The scientific director and vice-president of research at Lawson, Lisa Porter, left the organization last week. St. Joseph's has refused continuous interview requests from CBC News about its canine testing research and specifics on why it ended the program. In a statement sent to staff and media on Thursday, the hospital said it is "working on a transition plan to minimize the impact on our researchers and their work, which has resulted in major strides in cardiac care and treatment." The statement also said St. Joseph's plans to appoint an independent third party to review its animal-based research and is now turning its attention to in-hospital safety. "In the coming weeks, we will continue to focus on the safety and security of our staff, physicians, researchers, patients, residents and visitors," the statement said. The hospital has refused to answer CBC's questions about whether researchers or staff have received threats and if the hospital has hired any additional security over the last week for this reason. Higher risks for young researchers Adler said on the day he shut down his lab, he destroyed all documents that could identify the student researchers who were part of his canine trials, with both their safety and careers in mind. "If I'm going to be hunted down for my crimes, I intend to do it alone," he said, adding that the Premier's comments could impact other Masters-level researchers around the province. "Imagine a student who's put four years into their PhD and is reluctant to publish a thesis that would name them by name," Adler said. "Their enthusiasm for their work is now tempered by the threat." Adler said that he plans to move testing for his project outside of Ontario, and potentially out of the country, in order to continue developing the important new technology. "Vets have much less technology available to them than human doctors, and they're hungrier for innovation," he said.